Listening to the myeloma patient voice is difficult – but it still needs to be doneOver the last decade, treatments for the blood cancer myeloma have come on in leaps and bounds – Share XListening to the myeloma patient voice is difficult – but it still needs to be donehttps://pharmaphorum.com/views-analysis-patients/listening-myeloma-patient-voice-difficult-but-needs-to-be-done/
Myeloma UK launches stratified medicine trial of Darzalex comboResearch-based charities are taking on an ever-growing role in frontline clinical research, and Myeloma UK has just launched Share XMyeloma UK launches stratified medicine trial of Darzalex combohttps://pharmaphorum.com/news/myeloma-uk-launches-stratified-medicine-trial-darzalex-combo/
Amgen’s Kyprolis gains expanded myeloma use in EuropeKyprolis gains label expansion in Europe Share XAmgen’s Kyprolis gains expanded myeloma use in Europehttps://pharmaphorum.com/transversal-categories/uk-and-europe/amgens-kyprolis-gains-expanded-myeloma-use-europe/
Further Darzalex results extend hope for PFS in MyelomaEarlier this year (March), Johnson & Johnson announced that the randomized Phase III CASTOR trial (NCT02136134) achieved its Share XFurther Darzalex results extend hope for PFS in Myelomahttps://pharmaphorum.com/partner-content-oncology/further-darzalex-results-extend-hope-for-pfs-in-myeloma/
